K. Horwood

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses

Paul Mitchell, N. Thatcher, Mark A. Socinski et al. · Annals of Oncology · 2015 · 103 citations · Full text

Biomarker Analyses, Medicine, Immunology +6

Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival

Andreas Obermair, Robyn Cheuk, K. Horwood et al. · International Journal of Gynecological Cancer · 2003 · 38 citations

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Eun Young Kang, Dane Cheasley, Cécile Le Page et al. · Modern Pathology · 2020 · 38 citations · Full text

Tumor Heterogeneity, Medicine, Gynecology +9

The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC)

H. Groen, Óscar Arrieta, H. Riska et al. · Journal of Clinical Oncology · 2008 · 14 citations

Global Trust Study, Cancer Management, Pathology +17

Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study

U. Gatzemeier, Andrea Ardizzoni, K. Horwood et al. · Journal of Clinical Oncology · 2007 · 13 citations

Advanced Nsclc, Cancer Risk, Cancer Epidemiology +14